FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sagimet Biosciences Inc. - Series A Common Stock
(NQ:
SGMT
)
9.370
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sagimet Biosciences Inc. - Series A Common Stock
< Previous
1
2
3
Next >
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
October 01, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
September 30, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
September 30, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
September 28, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
September 02, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
August 25, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
August 13, 2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 11, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 04, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
June 29, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
May 27, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 12, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
May 11, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
April 27, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Provides Strategic and Corporate Updates
April 27, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
March 11, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
February 25, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
February 05, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 02, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
January 08, 2026
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
December 18, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
December 17, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
December 10, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
November 20, 2025
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
